ArticleSubstance abuse2020
Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
Article in Substance abuse, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 48 citations in OpenAlex.
- Harnessing telemedicine to deliver patient-centered opioid agonist treatment within a community-based harm reduction service: a mixed methods evaluation.Harm reduction journal · 2025Article
- Telepsychiatry in addiction treatment: Evaluating India's telemedicine guidelines.Indian journal of psychiatry · 2025Article
- Access and care for people with opioid use disorder in U.S. skilled nursing facilities: A policy commentary.The International journal on drug policy · 2024Article
- Integrating Buprenorphine for Opioid Use Disorder into Rural, Primary Care Settings.Journal of general internal medicine · 2024Article
- Access to treatment before and after Medicare coverage of opioid treatment programs.Health affairs scholar · 2024Article
- Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy.Substance abuse · 2023Article
- Changes to methadone maintenance therapy in the United States, Canada, and Australia during the COVID-19 pandemic: A narrative review.Journal of substance use and addiction treatment · 2023Review
- Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment.JAMA health forum · 2023Article
- Challenges of methadone maintenance treatment decentralisation from Vietnamese primary care providers' perspectives.Drug and alcohol review · 2023Article
- Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey.Harm reduction journal · 2023Article
- Buprenorphine Treatment Episodes During the First Year of COVID: a Retrospective Examination of Treatment Initiation and Retention.Journal of general internal medicine · 2023Article
- Characterization of Unintentional Deaths Among Buprenorphine Users.Journal of studies on alcohol and drugs · 2023Article
- Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.BMC psychiatry · 2022Article
- Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients.Drug and alcohol review · 2022Article
- The impact of COVID-19 on service delivery systems: evidence from a survey of United States refugee resettlement agencies.BMC health services research · 2022Article
- Substance, use in relation to COVID-19: A scoping review.Addictive behaviors · 2022Article
- Pharmacists expanded role in providing care for opioid use disorder during COVID-19: A qualitative study exploring pharmacists' experiences.Drug and alcohol dependence · 2022Article
- The Role of the Pharmacist in Combating the Opioid Crisis: An Update.Substance abuse and rehabilitation · 2022Review
- Opioid-Involved Overdose Vulnerability in Wyoming: Measuring Risk in a Rural Environment.Substance use & misuse · 2022Article
- Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis.Addiction science & clinical practice · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Medications for opioid use disorder (MOUD), such as methadone and buprenorphine, are effective strategies for treatment of opioid use disorder (OUD) and reducing overdose risk. MOUD treatment rates continue to be low across the US, and currently, some evidence suggests access to evidence-based treatment is becoming increasingly difficult for those with OUD as a result of the 2019 novel corona virus (COVID-19). A major underutilized source to address these serious challenges in the US is community pharmacy given the specialized training of pharmacists, high levels of consumer trust, and general availability for accessing these service settings. Canadian, Australian, and European pharmacists have made important contributions to the treatment and care of those with OUD over the past decades. Unfortunately, US pharmacists are not permitted to prescribe MOUD and are only currently allowed to dispense methadone for the treatment of pain, not OUD. US policymakers, regulators, and practitioners must work to facilitate this advancement of community pharmacy-based through research, education, practice, and industry. Advancing community pharmacy-based MOUD for leading clinical management of OUD and dispensation of treatment medications will afford the US a critical innovation for addressing the opioid epidemic, fallout from COVID-19, and getting individuals the care they need.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.